World Federation of Hemophilia
-
Update on Shire and Roche/Genentech patent dispute regarding Hemlibra
Update: On March 28, 2018, Chugai Pharmaceuticals, a subsidiary of Roche, announced that a Japanese court ruled that the hemophilia treatment product Hemlibra (emicizumab) does...
-
Important news for the bleeding disorders community
Important news that impacts the global bleeding disorders community was announced today, with Sanofi to acquire Bioverativ. Click here to read the Sanofi press release.
-
WFH closely monitoring Shire and Roche/Genentech patent dispute
The World Federation of Hemophilia has been closely monitoring the developing situation between Shire and Roche/Genentech and their dispute over patent ownership. We will continue...
-
Update: FDA lifts suspension of Fitusiran trial
The United States Food and Drug Administration has agreed to allow Alnylam’s clinical trial of the novel drug Fitusiran to resume. The FDA and Alnylam...
-
-
-
The WFH wishes you a happy new year
Wishing you a happy new year Meilleurs voeux pour la nouvelle année Deseamos un feliz año nuevo
-
The Africa Summit Declaration on Hemophilia and Other Inherited Bleeding Disorders
The World Federation of Hemophilia (WFH) Africa Summit on Hemophilia and Other Inherited Bleeding Disorders was held in Dakar, Senegal from November 28 to 29,...
-
-
Alnylam Suspends Fitusiran Dosing due to Thrombotic Event in Phase 2 open-label extension study
The WFH was saddened to learn of the death of a hemophilia A patient taking part in the Phase II trial of fitusiran, in development...
